工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
建立针对实体瘤和自身免疫性疾病的细胞疗法机构准备路线图
英文原题：A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.
查看英文原题
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过继性细胞疗法已彻底改变了血液系统恶性肿瘤的治疗，并在实体瘤和自身免疫性疾病中展现出潜力。真实世界的实施仍受限于生物学、物流和制造方面的障碍，尽管临床试验组合迅速扩展，却限制了全球范围内的应用。有效的实施需要国家和机构层面的准备、多学科协作、可扩展的生产制造以及稳健的基础设施。相关工作应优先发展去中心化和“即用型”平台、整合转诊网络以及AI辅助的患者管理，以支持安全、公平且高效的全球交付。
展开英文摘要原文
Adoptive cellular therapies have revolutionised treatment of haematological malignancies and demonstrate potential in solid tumours and autoimmune disease. Real-world implementation remains limited by biological, logistical, and manufacturing barriers, restricting global uptake despite a rapidly expanding clinical trial portfolio.
Effective implementation requires national and institutional readiness, multidisciplinary collaboration, scalable manufacturing, and robust infrastructure. Efforts should prioritise decentralised and "off the shelf" platforms, integrated referral networks, and AI-assisted patient management to support safe, equitable and efficient global delivery.
论文信息
- 作者
- Childs S、Ma D、Houghton E、Cosman R、Massey J、Chin V、Valencia V、O'Grady A
- 第一作者单位
- The Kinghorn Cancer Centre, St Vincent's Hospital Darlinghurst, Darlinghurst, NSW, Australia.Australia
- 通讯作者单位
- The Kinghorn Cancer Centre, St Vincent's Hospital Darlinghurst, Darlinghurst, NSW, Australia. jia.liu@svha.org.au.Australia
- 文献类型
- 综述
- 期刊
- NPJ precision oncology2026 May 7
- 原文标识
- PubMed 42098290 · DOI 10.1038/s41698-026-01462-6
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →